TherapeuticsMD (TXMD) Tops Q1 EPS by 1c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Stocks fall as higher oil prices, Treasury yields weigh
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
TherapeuticsMD Announces First Quarter 2021 Financial Results
May 6, 2021 7:00 AM EDT- 1Q21 total net revenue increased to $19.9 million -
- 1Q21 total net product revenue increased 60% to $19.6 million compared to 1Q20 -
- ANNOVERA prescriptions continue to grow with increasing consumer support and acceptance -
- Further strengthened ANNOVERA® patent family through June 2039
- Significantly improved average net revenue per unit for IMVEXXY® to $61 and BIJUVA® to $69 -
-vitaCares divesture process continues in an effort to unlock shareholder value-
- Conference call scheduled... More
